(Albany, US) DelveInsight has launched a new report on Non-Radiographic Axial Spondyloarthritis Market
DelveInsight’s “Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) – Market Insights, Epidemiology, and Market Forecast-2030” report delivers an in-depth understanding of the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA), historical and forecasted epidemiology as well as the Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market report provides current treatment practices, emerging drugs, Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market share of the individual therapies, current and forecasted Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.
Axial spondyloarthritis (axSpA) is an umbrella term inflammatory arthritis types that primarily affects the spine and the sacroiliac (SI) joints that connect the lower spine to the pelvis, resulting in pain in the lower back, hips, and buttocks. There are two subtypes of axSpA: Non-radiographic axial spondyloarthritis (nr-axSpA) and Ankylosing spondylitis (AS). “Non-radiographic” means that damage to the joints is not visible on X-ray. When changes to the vertebrae (the bones of the spine) or SI joints do not show any an X-ray changes, it is known as nr-axSpA. Once the joints are affected by an X-ray, a person can be diagnosed with AS. Up to 6% of people with chronic back pain will ultimately receive a diagnosis of axial spondyloarthritis. However, the disease often takes as long as 10 years to be diagnosed—a delay that can hugely impact your quality of life and lead to disability, missed time at work, and increased healthcare costs. Even worse, since the disease is progressive, you may become more debilitated over time. Left untreated, the vertebrae in your spine can fuse. Unfortunately, awareness of axial spondyloarthritis, including symptoms and what it takes to get diagnosed, is severely lacking. Here’s the scoop on this little-known disease.
View Free Sample Page:- https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nraxspa-market
Non-Radiographic Axial Spondyloarthritis Treatment
Non-pharmacological treatment (first of all, education and regular exercises) is considered to be of nearly the same importance as NSAIDs in the first-line therapy of axSpA. It is generally accepted that regular exercise/physiotherapy effectively reduces symptoms and increases function and spinal mobility in axSpA in a short-term perspective that is also supported by evidence. However, the influence of non-pharmacological treatment on the long-term outcomes and radiographic spinal progression is less clear. COSENTYX (secukinumab) is a prescription medicine used to treat adults with active non-radiographic axial spondyloarthritis and objective signs of inflammation.
Non-Radiographic Axial Spondyloarthritis Market
The Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market outlook of the report helps to build the detailed comprehension of the historic, current, and forecasted Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a thorough detail of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.
Non-Radiographic Axial Spondyloarthritis Report Scope
Download Free Sample Page:- https://www.delveinsight.com/sample-request/non-radiographic-axial-spondyloarthritis-nraxspa-market
Table of content
1. Key Insights
2. Executive Summary of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)
3. Competitive Intelligence Analysis for Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)
4. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA): Market Overview at a Glance
5. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA): Disease Background and Overview
6. Patient Journey
7. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Unmet Needs
10. Key Endpoints of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA) Treatment
11. Marketed Products
12. Emerging Therapies
13. Non-Radiographic Axial Spondyloarthritis (nr-AxSpA): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Non-Radiographic Axial Spondyloarthritis (nr-AxSpA)
17. KOL Views
18. Market Drivers
19. Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight
Why should you buy this report?
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Yash BhardwajEmail: Send EmailPhone: +919650213330Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/